In order to adapt to a higher proliferative rate and an increased demand for energy sources,
cancer cells rewire their metabolic pathways, a process currently recognized as a hallmark …

Developing novel therapeutics often follows three steps: target identification, design of
strategies to suppress target activity and drug development to implement the strategies. In …

The lethality and chemotherapy resistance of pancreatic cancer necessitates the urgent
development of innovative strategies to improve patient outcomes. To address this issue, we …

Background Glioblastoma (GBM), a prevalent malignant neoplasm within the neuro-
oncological domain, has been a subject of considerable scrutiny. Macrophages, serving as …

Cellular responses to hypoxia are crucial in various physiological and pathophysiological
contexts and have thus been extensively studied. This has led to a comprehensive …

Cisplatin (cis) is a first-line chemotherapeutic used for the treatment of intractable pediatric
brainstem glioma (PBSG). Its therapeutic effect in PBSG is, however, critically challenged by …

The search for more effective and selective drugs to overcome cancer multidrug resistance
is urgent. As such, a new series of ruthenium-cyclopentadienyl (“RuCp”) compounds with …

Animal models are routinely employed to assess the treatments for human cancer. However,
due to significant differences in genetic backgrounds, traditional animal models are unable …

Myeloid-derived suppressor cells (MDSCs) are a population of immature bone marrow cells
that accumulate in large numbers in the spleen, peripheral blood, bone marrow, lymph …

Feline leukemia virus C receptor 1a (FLVCR1a), initially identified as a retroviral receptor
and localized on the plasma membrane, has emerged as a crucial regulator of heme …